Notably, these inhibitors rely on the intrinsic GTPase of mutant KRASG12C, i.e., the KRASG12C protein is still able to alternate between their active and inactive state, as GTP-bound KRAS is the predominant form in KRASG12C-mutant cancer cells. The gene discussed is KRAS; the disease is cancer.